Literature DB >> 209810

Further clinical experiences of a phase I study with the hypoxic cell radiosensitizer misonidazole.

H D Kogelnik, J H Meyer, K Jentzsch, T Szepesi, K H Kärcher, E Maida, B Mamoli, P Wessely, F Zaunbauer.   

Abstract

Since April 1976 we have performed clinical investigations with multiple doses of the hypoxic cell radiosensitizer misonidazole in 21 patients. A significant side effect of the drug was the development of peripheral sensory neuropathies in 13 patients (8 mild, 5 severe) and of a transient acute organic psychosyndrome in 2 of the 5 patients with a severe polyneuropathy. The severity of the polyneuropathies is related to the total dose of misonidazole and the overall time of drug administration. Treatment schedules designed to obtain the desired sensitizing effect without neurological side effects are under investigation.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 209810      PMCID: PMC2149409     

Source DB:  PubMed          Journal:  Br J Cancer Suppl        ISSN: 0306-9443


  9 in total

1.  HYDRATED ELECTRONS AND RADIOBIOLOGICAL SENSITISATION.

Authors:  G E ADAMS; D L DEWEY
Journal:  Biochem Biophys Res Commun       Date:  1963-08-20       Impact factor: 3.575

2.  Radiosensitizers of hypoxic cells in solid tumors.

Authors:  J F Fowler; G E Adams; J Denekamp
Journal:  Cancer Treat Rev       Date:  1976-12       Impact factor: 12.111

3.  Optimum fractionation of the C3H mouse mammary carcinoma using x-rays, the hypoxic-cell radiosensitizer Ro-07-0582, or fast neutrons.

Authors:  J F Fowler; P W Sheldon; J Denekamp; S B Field
Journal:  Int J Radiat Oncol Biol Phys       Date:  1976 Jul-Aug       Impact factor: 7.038

4.  Clinical testing of the radiosensitiser Ro-07-0582. I. Dose tolerance, serum and tumour concentrations.

Authors:  A J Gray; S Dische; G E Adams; I R Flockhart; J L Foster
Journal:  Clin Radiol       Date:  1976-04       Impact factor: 2.350

5.  Letter: An investigation of the pharmacological and radiosensitizing effects of the 2-nitroimidazole Ro-07-0582 in primates.

Authors:  R Johnson; C Gomer; J Ambrus; J Pearce; D Boyle
Journal:  Br J Radiol       Date:  1976-03       Impact factor: 3.039

6.  Clinical testing of the radiosensitiser Ro-07-0582. III. Response of tumours.

Authors:  R H Thomlinson; S Dische; A J Gray; L M Errington
Journal:  Clin Radiol       Date:  1976-04       Impact factor: 2.350

7.  Metronidazole neuropathy.

Authors:  A Coxon; C A Pallis
Journal:  J Neurol Neurosurg Psychiatry       Date:  1976-04       Impact factor: 10.154

8.  Clinical phase I study of the hypoxic cell radiosensitizer RO-07-0582, a 2-nitroimidazole derivative.

Authors:  R C Urtasun; P Band; J D Chapman; H R Rabin; A F Wilson; C G Fryer
Journal:  Radiology       Date:  1977-03       Impact factor: 11.105

9.  Clinical testing of the radiosensitizer Ro 07-0582: experience with multiple doses.

Authors:  S Dische; M I Saunders; M E Lee; G E Adams; I R Flockhart
Journal:  Br J Cancer       Date:  1977-05       Impact factor: 7.640

  9 in total
  4 in total

1.  Cell-cycle inhibition by misonidazole of human cells cultivated in vitro under aerobic conditions.

Authors:  T Lindmo; E O Pettersen; E Wibe
Journal:  Br J Cancer       Date:  1979-11       Impact factor: 7.640

2.  Changes in nerve conduction velocity in the mouse after acute and chronic administration of nitroimidazoles.

Authors:  D G Hirst; B Vojnovic; B Hobson
Journal:  Br J Cancer       Date:  1979-02       Impact factor: 7.640

3.  Effect of acute and chronic misonidazole administration on peripheral-nerve electrophysiology in mice.

Authors:  P J Conroy; R Von Burg; D P Penney; W Passalacqua; R M Sutherland
Journal:  Br J Cancer       Date:  1980-04       Impact factor: 7.640

4.  Peripheral electrophysiological parameters in mice treated with misonidazole.

Authors:  R Von Burg; P J Conroy; W Passalacqua
Journal:  Br J Cancer       Date:  1979-07       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.